Effective treatment of high blood pressure (BP) represents a key strategy for reducing the burden of hypertension-related cardiovascular and renal diseases. In spite of these well-established concepts, hypertension remains poorly controlled worldwide. In order to improve BP control in patients with hypertension, several interventions have been proposed, among which (1) preferred use of more effective, sustained, and well-tolerated antihypertensive drug aimed to ensure adherence to prescribed medications and (2) extensive use of rational, integrated, and synergistic combination therapies, even as first-line strategy, aimed to achieve the recommended BP targets. Within the possible antihypertensive drug classes currently available for the clinical management of hypertension, both in monotherapy and in combination therapy, drugs inhibiting the renin-angiotensin system and calcium channel blockers (CCBs) have demonstrated to be effective and safe in lowering BP levels and achieving the recommended BP targets with a good tolerability profile. In particular, CCBs have been one of the most widely used classes of antihypertensive agents in the last 20 years, based on their effectiveness in reducing BP levels, good tolerability, and abundant evidence on reducing cardiovascular and renal consequences of hypertension. This article provides an updated overview of the evidence supporting the use of CCBs-based antihypertensive regimen, both in monotherapy and in combination therapies with different classes of antihypertensive drugs.

Calcium Channel Blockers and Hypertension / Tocci, Giuliano; Battistoni, Allegra; Passerini, Jasmine; Musumeci, Maria Beatrice; Francia, Pietro; Ferrucci, Andrea; Volpe, Massimo. - In: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS. - ISSN 1074-2484. - STAMPA. - 20:(2014), pp. 121-130. [10.1177/1074248414555403]

Calcium Channel Blockers and Hypertension.

TOCCI, GIULIANO;BATTISTONI, ALLEGRA;PASSERINI, JASMINE;MUSUMECI, Maria Beatrice;FRANCIA, Pietro;FERRUCCI, Andrea;VOLPE, Massimo
2014

Abstract

Effective treatment of high blood pressure (BP) represents a key strategy for reducing the burden of hypertension-related cardiovascular and renal diseases. In spite of these well-established concepts, hypertension remains poorly controlled worldwide. In order to improve BP control in patients with hypertension, several interventions have been proposed, among which (1) preferred use of more effective, sustained, and well-tolerated antihypertensive drug aimed to ensure adherence to prescribed medications and (2) extensive use of rational, integrated, and synergistic combination therapies, even as first-line strategy, aimed to achieve the recommended BP targets. Within the possible antihypertensive drug classes currently available for the clinical management of hypertension, both in monotherapy and in combination therapy, drugs inhibiting the renin-angiotensin system and calcium channel blockers (CCBs) have demonstrated to be effective and safe in lowering BP levels and achieving the recommended BP targets with a good tolerability profile. In particular, CCBs have been one of the most widely used classes of antihypertensive agents in the last 20 years, based on their effectiveness in reducing BP levels, good tolerability, and abundant evidence on reducing cardiovascular and renal consequences of hypertension. This article provides an updated overview of the evidence supporting the use of CCBs-based antihypertensive regimen, both in monotherapy and in combination therapies with different classes of antihypertensive drugs.
2014
01 Pubblicazione su rivista::01a Articolo in rivista
Calcium Channel Blockers and Hypertension / Tocci, Giuliano; Battistoni, Allegra; Passerini, Jasmine; Musumeci, Maria Beatrice; Francia, Pietro; Ferrucci, Andrea; Volpe, Massimo. - In: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS. - ISSN 1074-2484. - STAMPA. - 20:(2014), pp. 121-130. [10.1177/1074248414555403]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/624797
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 26
social impact